How Deep Does the Needle Go?

Two different questions get asked with the same word. Gauge is how wide the needle is, and it decides how hard the liquid is to push and how much the entry stings. Length is how deep it goes, and it decides which tissue the drug actually lands in. This article is about length.

Getting length wrong does not usually hurt. That is the problem with it. An injection intended for muscle that lands in fat still goes in, still feels normal, and still empties the syringe. What changes is where the drug sits and how fast it leaves, and you have no way to notice that from the outside.

The one fact that explains most of it

Skin thickness barely varies between people. Subcutaneous fat thickness varies enormously.

This is the finding that makes needle-length advice tractable, and it is not intuitive. In an ultrasound study of 388 adults measuring the sites used for insulin injection, mean skin thickness came out between roughly 1.9 and 2.4 mm across the arm, thigh, abdomen and buttock, and it varied remarkably little with body mass index, sex, age or ethnicity.¹ The fat beneath it, over the same people and the same sites, ranged from a few millimetres to several centimetres.

So the depth at which subcutaneous tissue starts is close to a constant. The depth at which it ends, and muscle begins, is not. That asymmetry runs through everything below: aiming for subcutaneous tissue is an easy target that almost any needle hits, and aiming for muscle is a harder target that a standard needle often misses.

Subcutaneous: the easy target

If subcutaneous tissue begins about 2 mm down in nearly everyone, a short needle is enough. The large insulin-delivery consensus recommendations reached exactly that conclusion: a 4 mm pen needle is adequate for adults regardless of body mass index, and it is preferred precisely because longer needles add risk without adding benefit.²

The risk being avoided is going too far. A needle long enough to cross a thin person’s fat layer deposits into muscle instead, and intramuscular delivery of something intended to sit in fat absorbs faster and less predictably.³ This is most likely in lean people and at limb sites, where there is least fat to cross.

For peptide work this mostly resolves itself, because the standard tool is an insulin syringe with a fixed short needle:

• 8 mm (5/16 inch) and 12.7 mm (1/2 inch) are the common fixed needles on U-100 insulin syringes
• 29 to 31 gauge is the usual bore on those syringes
• A pinched skinfold lifts fat away from muscle and is the standard mitigation when the needle is long relative to the site

A 12.7 mm needle inserted straight into a lean thigh or arm can reach muscle. Pinching, or injecting at 45 degrees, shortens the effective depth. This is well-established technique in the insulin literature and transfers directly, because it is a fact about tissue rather than about the drug.

Intramuscular: the target that gets missed

Muscle is a harder target, and the evidence here is uncomfortable. Several imaging studies have asked whether injections intended as intramuscular actually reached muscle, and repeatedly found that many did not.

The problem concentrates at the dorsogluteal site, the upper-outer buttock that most people picture when they think of a glute shot. Retrospective and CT-based work found that the subcutaneous fat layer there frequently exceeds the length of a standard needle, so the drug is deposited into fat while everyone involved believes it went into muscle.⁴ The effect is strongly sex-linked, because of where fat distributes: women are considerably more likely to be affected at that site than men at the same body weight.

Three practical consequences follow, and they are the useful part of this section:

• The ventrogluteal site has less fat over it than the dorsogluteal site, which is the main reason the nursing and injection-technique literature has moved toward recommending it. It is also further from the sciatic nerve and the superior gluteal artery.
• Needle length for intramuscular injection is a function of the person, not of the drug. A 1-inch needle is adequate for many adults at many sites and inadequate for others at the same sites. Standard practice for larger patients is a 1.5-inch needle at gluteal sites.
• The deltoid is the most forgiving site, with relatively thin overlying fat in most adults, which is why vaccines default to it. Its constraint is the opposite one: too long a needle risks bone and the axillary nerve, so length is capped rather than extended.

TRT oils versus aqueous peptides

These are different liquids and the differences change what equipment works, so it is worth separating them.

Volume. A testosterone dose is commonly 0.25 to 1 mL of oil. A peptide dose is commonly 0.05 to 0.3 mL of water. That difference alone drives most of the equipment gap: an insulin syringe holds 1 mL at most and is graduated for small volumes, which suits peptides and is marginal for oils.

Viscosity. Testosterone esters are dissolved in a carrier oil, usually cottonseed, sesame or grapeseed, and oil is far more viscous than water. Viscosity is what makes gauge matter for oils and largely irrelevant for peptides. Pushing oil through a 29 gauge insulin needle is slow rather than impossible; pushing it through a 25 gauge needle is unremarkable. The common arrangement is to draw with a wide needle and inject with a narrow one, because drawing viscous oil through a fine needle is the slowest part of the process and the injection itself does not need the same bore.

Route. The folklore that testosterone must go intramuscularly has not held up. Subcutaneous administration has been studied and is now the basis of an approved weekly auto-injector product, and the comparative work has generally found subcutaneous dosing achieves serum levels comparable to intramuscular dosing with smaller needles and less discomfort.⁵ That does not make every ester or every concentration equivalent, and it is not a recommendation; it is a note that the “IM only” claim is a convention that the evidence has moved past.

The practical upshot is that the equipment question and the route question are separate. If the route is subcutaneous, the depth problem largely disappears for oils exactly as it does for peptides, and what remains is a viscosity and volume problem.

What we do not know

This is the section that matters most, because the evidence base here is borrowed.

• Almost none of the measurement evidence comes from peptides or from testosterone. The skin-thickness and needle-length work is from insulin delivery; the “did it reach muscle” imaging work is from clinical intramuscular injections generally. The anatomy transfers because it is anatomy. The dosing consequences may not transfer in magnitude.
• There is no trial of needle length for research peptides, and there is unlikely ever to be one. Everything in this article applied to a peptide is an inference from tissue depth, not a measured outcome.
• Population means do not describe an individual. Every number here is an average with a wide spread around it. Your fat thickness at a given site is not knowable from a table, and the only way to actually measure it is imaging.
• Absorption differences between fat and muscle are documented for insulin and for vaccines, not for most of what this site covers. That a misplaced injection absorbs differently is well established in general; how much it matters for a specific peptide at a specific dose is usually unstudied.

Conclusion

Skin is about 2 mm thick in almost everyone, and the fat under it is not, which is why subcutaneous injection is an easy target and intramuscular injection is a harder one. For subcutaneous work the short fixed needle on an insulin syringe is adequate and the main risk is a needle that is too long rather than too short. For intramuscular work the honest position is that a standard needle misses muscle in a meaningful fraction of people, most often at the dorsogluteal site and most often in women, which is the reason the literature favours the ventrogluteal site instead.

Oils and peptides differ in viscosity and volume rather than in anatomy. The depth reasoning is the same for both; the gauge and syringe choices are not.

References